Tallman Jacob E, Vertosick Emily A, Alam Syed M, Baky Fady J, Donat S Machele, Pietzak Eugene J, Cha Eugene K, Donahue Timothy F, Bochner Bernard H, Vickers Andrew J, Goh Alvin C
Division of Urology, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
J Urol. 2025 Apr;213(4):437-446. doi: 10.1097/JU.0000000000004387. Epub 2024 Dec 12.
Ureteral stents are commonly placed intraoperatively during radical cystectomy, although their efficacy in reducing complications is unproven. We compared clinical outcomes among patients undergoing robot-assisted radical cystectomy with intracorporeal ileal conduit (RARC-IC) with or without ureteral stents to determine if omission of ureteral stents affects postoperative complications.
All RARC-IC surgeries performed at our institution between November 2017 and June 2023 were reviewed. Beginning August 2021, ureteral stents were routinely omitted. Primary outcome was ureteroenteric anastomosis complications (urine leak, UTI, abscess, and/or sepsis) within 30 and 90 days of RARC-IC. Secondary outcomes included rates of wound infections, urgent care center visits, inpatient readmissions, and ureteral stricture.
Among 133 patients included, 90 patients (68%) received a ureteral stent and 43 (32%) did not. Composite ureteroenteric anastomosis complications were higher in the stented group (20% vs 9.5%, 10% difference, 95% CI, -3.4% to 24%, = .2), though not statistically significant. The stented group had a significantly higher 30-day UTI rate (19% difference, 95% CI, 9.0%-29%, = .007). The 30-day readmission rates were higher in the stented group, although differences did not meet statistical significance (19% vs 9.8%, 9.1% difference, 95% CI, -4.8% to 23%, = .3). Limitations include lack of randomization and inability to evaluate some outcomes, including ureteral obstruction or strictures.
Omission of ureteral stent placement at RARC-IC is safe and feasible. Randomized trials are warranted to determine the effects of stents on risk of postoperative complications after RARC-IC.
输尿管支架通常在根治性膀胱切除术术中放置,但其在减少并发症方面的疗效尚未得到证实。我们比较了接受机器人辅助根治性膀胱切除术并进行体内回肠代膀胱术(RARC-IC)的患者中,使用或不使用输尿管支架的临床结果,以确定省略输尿管支架是否会影响术后并发症。
回顾了2017年11月至2023年6月在我们机构进行的所有RARC-IC手术。从2021年8月开始,常规省略输尿管支架。主要结局是RARC-IC术后30天和90天内的输尿管肠吻合口并发症(尿漏、尿路感染、脓肿和/或败血症)。次要结局包括伤口感染率、紧急护理中心就诊率、住院再入院率和输尿管狭窄。
在纳入的133例患者中,90例(68%)接受了输尿管支架,43例(32%)未接受。支架置入组的复合输尿管肠吻合口并发症更高(20%对9.5%,差异10%,95%CI,-3.4%至24%,P = 0.2),尽管无统计学意义。支架置入组的30天尿路感染率显著更高(差异19%,95%CI,9.0%-29%,P = 0.007)。支架置入组的30天再入院率更高,尽管差异未达到统计学意义(19%对9.8%,差异9.1%,95%CI,-4.8%至23%,P = 0.3)。局限性包括缺乏随机分组以及无法评估某些结局,包括输尿管梗阻或狭窄。
在RARC-IC手术中省略输尿管支架置入是安全可行的。有必要进行随机试验以确定支架对RARC-IC术后并发症风险的影响。